Ministry of Science and Technology approves AstraZeneca’s technology transfer for pharmaceutical production in Vietnam

On October 10th, 2023, AstraZeneca announced that the Ministry of Science and Technology has issued a certificate of technology transfer registration for AstraZeneca to transfer the technology of production and packaging processes to Medochemie to produce innovative pharmaceutical products in Read More …

AstraZeneca Vietnam receives special BritCham award for innovation, sustainability, and healthcare impact

AstraZeneca Vietnam has been honoured with the British Chamber of Commerce (BritCham)’s first-ever 50th Anniversary Recognition award. The award acknowledges the company’s unwavering commitment to innovation, sustainability, and its profound impact on Vietnam’s healthcare sector. This recognition comes as part Read More …

Boosting with AstraZeneca’s vaccine provides high protection against Omicron, equivalent to mRNA COVID-19 vaccines

Boosting with AstraZeneca’s vaccine and mRNA COVID-19 vaccines provide equally high protection against Omicron-related severe outcomes, including hospitalisation and death, even as new subvariants of the virus emerge, according to an expert review of more than 50 real-world studies. The Read More …

AstraZeneca’s COVID-19 vaccine estimated to have prevented 232,766 deaths in Vietnam

With more than 72 million doses delivered to Vietnam, AstraZeneca’s COVID-19 vaccine is one of the most used in the country and is estimated to have prevented 232,766 deaths locally, an independent assessment of vaccine effectiveness shows.1,2 AstraZeneca’s vaccine was Read More …

Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial

Results published in The Lancet Respiratory Medicine support benefits of Evusheld in the outpatient treatment of mild-to-moderate COVID-19 Detailed results from the TACKLE Phase III outpatient treatment trial showed AstraZeneca’s Evusheld (tixagevimab and cilgavimab, formerly AZD7442) provided clinically and statistically Read More …

AstraZeneca to supply the US government with an additional one million doses of Evusheld long-acting antibody combination for the prevention of COVID-19

Builds on initial US government agreement, now totalling 1.7 million doses  Only antibody therapy authorized in the US for pre-exposure prophylaxis of COVID-19 in people who are immunocompromised AstraZeneca today announced the US Department of Health and Human Services has Read More …

Vaxzevria significantly boosted antibody levels against Omicron

University of Oxford study supports use of Vaxzevria as third dose booster against Omicron Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant AstraZeneca’s Read More …

Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study

Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19 In this pre-clinical study, Evusheld’s Inhibitory Concentration 50 (IC50), a measure of neutralising potency of an antibody, was 171 ng/ml and 277 ng/ml in two confirmatory tests, which is within the Read More …

30 million vaccine doses delivered to Vietnam via AstraZeneca-VNVC partnership

AstraZeneca and Vietnam Vaccine JSC (VNVC) have delivered an additional 1,547,100 doses of COVID-19 Vaccine AstraZeneca (also known as Vaxzevria) to Vietnam, reaching the milestone of 30 million doses and completing the first phase of the companies’ vaccine supply partnership, Read More …